Cytomedix Announces Extension of Exclusivity Period to Global Pharmaceutical Company for Autologel System in Chronic Wound Market

Regenerative therapies company Cytomedix announced an extension of the exclusivity period and an agreement with the top 20 global pharmaceutical company to negotiate a distribution agreement of the AutoloGel System in the U.S. chronic wound care market.... [more]

View complete Press Release article